GCP
JAZZ icon

Gill Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gill Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378 Buy
+2
New +$350 ﹤0.01% 646

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Gill Capital Partners's JAZZ Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 2 shares worth $378. The stake represents ﹤0.01% of the portfolio and ranks #646 among its holdings.

570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Gill Capital Partners held 2 shares of Jazz Pharmaceuticals worth $378 as of Q1 2026.
  • Jazz Pharmaceuticals was a new Gill Capital Partners position in Q1 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #646 holding.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.